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 Survival of biological cells depends on the biological cell’s ability to generate 
energy necessary for survival.  One of the most intriguing organelles inside eukaryotic 
cells is the mitochondrion, which is responsible for generating most of the energy 
required by the cell.  Mitochondrion is composed of two membranes, an outer 
membrane that surrounds the entire mitochondrion and an inner membrane which has a 
convoluted architecture that encapsulates a space called the mitochondrial matrix.  The 
space between the two membranes is called the inter-membrane space.  Four 
transmembrane electron transfer complexes (commonly called Complex I – IV)   and a 
transmembrane adenosine tri-phosphate (ATP) synthase complex (Complex V) are 
housed in the inner membrane. Complexes I, III and IV all pump protons from the 
mitochondrial matrix to the intermembrane space allowing for the build up of a proton 
gradient across the mitochondrial inner membrane (Figure 1).  The proton gradient is 
used by Complex V for the generation of ATP.  The ATP molecule consists of an 
adenine nucleotide plus two other phosphate groups.  ATP transfers energy that is 
stored in the covalent bond between the third and second phosphate to endergonic 
reactions in the cell.  This covalent bond is known as the “high energy” bond because 
when it is removed by hydrolysis a significant amount of energy is released.  
Approximately 7.0 kcal per mole of energy is released from the “high energy” bond, 
although the exact amount of released energy will depend on the conditions of  bond 










































Navigation of electrons through the respiratory chain begins with nicotinamide 
adenine dinucleotide (NADH) dehydrogenase (Complex I).  Complex I is the largest of 
the electron transport proteins, with 43 subunits and a mass of approximately 900kD.   
The overall shape of Complex I is similar to the letter “L” with the vertical part of the 
“L” in the membrane (the stalk) and the lower horizontal part of the “L” (the soluble 
globular arm) in the matrix, with the exception that the lower horizontal part of 
Complex I is much larger than the vertical stalk part.  Recently the crystal structure of 
the soluble globular arm of Complex I was solved at 3.3 Å resolution from Thermus 
thermophilus, which contains eight subunits along with all the redox centers of the 
enzyme, protein data bank (pdb) code (2fug) (1).  Complex I allows a pathway for 
electrons to transfer from the NADH-binding site in the arm to the quinone-binding site 
in the stalk, resulting in the generation of a quinol molecule from the pool of quinone in 
the intermembrane space.  In the process of Complex I generating a molecule of quinol 
four protons from the mitochondrial matrix are pumped to the intermembrane space.  
Several prosthetic groups in Complex I participate in electron transfer allowing for the 
electron to travel from the NADH binding site to the quinone binding site.     
 Succinate dehydrogenase (Complex II) is a membrane protein that does not pump 
protons but it does contribute to the ubiquinol pool.  Complex II catalyzes the oxidation 
of succinate to generate a molecule of ubiquinol. The structure of Complex II has been 
solved from Escherichia coli at a resolution of 3.1 Å (pdb code 2acz) and chicken heart 
at a resolution of 2.0 Å (2,3) . 
 Ubiquinol is utilized by ubiquinol cytochrome c oxidoreductase (Complex III) or 
(bc1 complex) to transfer electrons to the soluble cytochrome c in the intermembrane 
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space along with the translocation of protons from the mitochondrial matrix to the 
mitochondrial intermembrane space.  The functioning of the bc1 complex is commonly 
described by the proton motive Q cycle, which is a hypothesis used to describe the 
navigation of electrons from the electron donor ubiquinol to the electron acceptor 
cytochrome c. 
Cytochrome c oxidase (Complex IV) is the final enzyme to interact with electrons 
originating from the oxidation of metabolic fuels.  Complex IV is a dimeric 
transmembrane electron transfer protein consisting of 13 subunits per monomer in the 
mammalian complex.  The crystal structure of Complex IV has been solved at 2.3Å 
resolution (pdb code 2occ).  Complex IV functions by oxidizing the soluble 
cytochrome c and reducing molecular oxygen to water.  Complex IV also pumps 4 
additional protons from the matrix to the intermembrane space, which would correlate 
to two protons for every pair of electrons from cytochrome c. 
 Complex V utilizes the proton gradient generated by Complexes I, III and IV to 
phosphorylate adenosine diphosphate (ADP).  Complex V consists of two parts F1 
(the soluble part which resides in the matrix) and Fo (the hydrophobic part which 
resides in the mitochondrial innermembrane (Figure 1).  The Fo part lets the flow of 
protons back into the matrix and the F1 part synthesizes the adenosine triphosphate 
(ATP) from ADP. 
 The study of the respiratory chain reveals several remarkable aspects of the 
metabolic process; in particular the way electron transfer complexes couples the 
transfer of electrons to the translocation of protons.  Crystallography has played an 
important role in deciphering the complex attributes of the electron transfer proteins.    
 5
Cytochrome bc1 Complex 
 
 
The bovine mitochondrial bc1 complex is a dimeric transmembrane protein that 
consists of 11 subunits with a dimeric molecular weight of about 500 kDa (Figure 2) 
(Table I) (3).  The largest subunits in the mitochondrial bc1 complex as seen in table I 
are core 1 and core 2.  Core1 and core2 have sequence homology to zinc proteases, 
and function in the cleavage and retention of the iron sulfur protein subunit (ISP) 
presequence, in which the ISP presequence becomes subunit 9 in the bc1 complex (4-
6). 
Three subunits out of the eleven total subunits are essential for electron transfer in 
Complex III (Figure 4).  The three essential subunits are cytochrome b (cyt. b) which 
contains low and high potential b-type hemes (bL and bH), cytochrome c1 (cyt. c1) 
which contains a c-type heme, and ISP which contains a 2Fe-2S cluster (FeS).  
Distances between the hemes and the FeS are shown in figure 5.  The bacterial bc1 
complex in Rhodobacter sphaeroides contains homologues of the three essential 
subunits from bovine and supernumerary fourth subunit termed subunit 4.  
Rodobacter capsulatus bacterial bc1 complex only contains 3 subunits which are the 
homologues of the three essential subunits in bovine.  The x-ray crystal structure for 
the Rodobacter capsulatus bc1 complex has been solved at 3.5 Å resolution and 
reveals the identity of structurally conserved regions in the bc1 complex (7).  Site-
directed mutagenesis studies in bacterial bc1 complexes have significantly advanced 
the study of deciphering the important role conserved residues play in the bc1 






Figure 2. Bovine bc1 Complex. (B) is a ninety degree rotation of (A). 
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Table I. Subunits of the bovine bc1 complex 
 
 
Subunit  Name   aaa  IDb
 
  1   Core 1   446  P31800 
  2   Core 2   439  P23004 
  3   Cyt. b   379  P00157 
  4   Cyt c1   241  223266 
  5   ISP   196  P13272 
  6   QPK   110  P00129 
  7   QPC      81  P13271 
  8   Hinge       78  P00126 
  9   Subunit 9            57  P13272 
10   Subunit 10            62  P00130 
11   Subunit 11            56  P07552 
 
 
a Number of amino acid residues 
















Figure 3. Dimer of the three essential subunits in the bc1 complex. Where cyt b is 
green and represents the membrane region, ISP is yellow, and cyt c1 is blue. 
 
Figure 4. Distances between iron atoms in angstroms. 
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  The first three-dimensional atomic level resolution crystal structure of 
cytochrome bc1 complex from bovine heart mitochondria was solved at 2.9 Å 
resolution where majority of the bc1 complex was modeled in including core 1, core 
2, cyt. b, subunit 6, subunit 7, a carboxyl-terminal fragment of cyt. c1, and an amino-
terminal fragment of ISP (8).  Afterwards, more complete bc1 complex structures 
were reported (9-11). 
The subunit which houses the bc1 complex substrates and various inhibitors is cyt. 
b which has eight alpha helices labeled A-H, and resides mainly in the membrane 
(Figure 6).  Helices B and D contain the histidine residues which are responsible for 
holding cyt. bL heme and cyt. bH heme in place.   A surface rendering of the 
cytochrome b subunit reveals 4 major cavities as depicted in figure 6.  The ISP head 
domain docking cavity exterior is defined by cyt b residues Trp141, Thr144, Ser151, 
Ser169, Leu262, Thr264, Pro266, Pro285, Lys287, Val343 which is where the ISP 
head domain that contains the FeS docks.  The exterior of the Qo site cavity is defined 
by cyt. b residues Ile146, Leu149, Phe274, Val291, Leu294.  The Qm site cavity 
exterior is defined by residues Trp30, Ile92, Met96, Trp272, Trp326, Val329, 
Leu333, Thr336  and the Qi site cavity exterior consists of residues Phe18, Ile39, 
Ile42, Met194.  The Qo and Qi sites are binding sites for the substrates ubiquinol and 
ubiquinone respectively.  The inhibitors for the bc1 complex have been categorized as 
P or N to denote which binding site the inhibitors bind in, P for the Qo site and N for 
the Qi site (Figure 7) (12,13).  The Qo site inhibitors have been further classified as Pf 
for the ability to fix the ISP head domain and Pm if the inhibitor keeps the ISP head 
domain in the mobile state (12). 
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A     B  
C      D  
 
Figure 6. Major cavities in cytochrome b.  (B) is a 90 rotation of (A), (C) is a 90 
degree rotation of (B), and (D) is a 90 rotation of (C).  ISP head domain docking 












Antimycin A Ubiquinone  














            B. Qo site inhibitors, and substrate quinol.   
  
            Figure 7.  bc1 complex inhibitors and substrates.                  







The Qo Site 
 
     The Qo substrate binding site of the native bc1 has a shape similar to that of a 
funnel (14).  The outside of the binding site has a relatively wide opening and the 
cross sectional area becomes narrower moving inward.  The Qo binding site is highly 
hydrophobic and surrounded by aromatic residues in addition to a number of aliphatic 
residues.  The top of the Qo binding site is capped off with His161, which is part of 
the 2Fe-2S cluster in the ISP subunit, when the ISP head domain is docked onto the 
cytochrome b subunit.  The Qo binding site has a considerable amount of conserved 
residues that may interact with the substrate in a manor similar to that of the 
inhibitors during the various functional stages of enzymatic activity.  
MOAS in the Qo binding site 
     MOAS, 3-methoxy-2-(2-styryl-phenyl)-acrylic acid methyl ester, consists of a 
methoxy methyl acrylate group (toxophore) and a stilbene moiety (Figure 7).  MOAS 
is derived from strobilurin and is a synthetic anti-fungal agent.  One hydrogen bond is 
formed between the backbone amide group of Glu271 and the oxygen atom O3 in 
MOAS.  The binding environment for MOAS consists of several aromatic residues, 
Phe274, Phe128, Tyr273, and Tyr131.  A parallel displaced pi-stacking interaction is 
formed between the aromatic ring of Phe274 and the styryl moiety of MOAS.  The 











Interactions shown in the LIGPLOT representation are those mediated by hydrogen 
bonds and by hydrophobic contacts.  Hydrogen bonds are indicated by dashed lines 
between the atoms involved, while hydrophobic contacts are represented by an arc 
with spokes radiating towards the ligand atoms they contact (15).  The contacted 
atoms are shown with spokes radiating back.  The LIGPLOT representation is a two-
dimensional representation of how the ligand is binding in the binding site of the 
enzyme.  LIGPLOT representation of the binding site allows for a quick analysis of 
important contacts between the ligand and residues in the binding site.  In the 
LIGPLOT representation all residues interacting with the ligand are shown.  Three-
dimensional figures will typically have residues that make up the binding site 
removed to allow for the viewing of the substrate with hydrogen bonding residues.  
The three-dimensional viewing is best achieved with molecular graphics software. 
Myxothiazol in the Qo site. 
     Myxothiazol is an anti-fungal inhibitor that is produced by myxobacterium 
Myxococcus fulvus.  Myxothiazol has an active methoxyacrylamide group and a 
dithiazole moiety.  An amide functional group is one of the characteristics that 
separate myxothiazol from other MOA type inhibitors.  Phe274 may play a role in 
aromatic-aromatic interactions with the diathiazol moiety to stabilize myxothiazol in 
the binding site.  Two hydrogen bonds are formed between myxothiazol and residues 
in the Qo site.  A hydrogen bond is formed between the hydroxyl group of Tyr273 and 
the amide nitrogen atom N1 of myxothiazol.  The second hydrogen bond is formed 
between the backbone amide of Glu271 and the amide oxygen atom O1 of 
myxothiazol.  The binding of myxothiazol in the Qo binding site is shown in figure 9. 
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Famoxadone in the Qo binding site 
     Famoxadone, 5-methyl-5-(4-phenoxy-phenyl)-3- phenylamino-2,4 
oxazolidinedione, is a Qo site bc1 complex inhibitor(Figure 7). One hydrogen bond is 
found between famoxadone oxygen atom O6 of the oxazolidine-2,4- dione ring and 
the amide group of Glu271 with a distance of 2.57 Å.  A hydrogen bond is also 
possible between the secondary amine N2 of famoxadone and a water molecule. The 
famoxadone, hydrogen bonding, water molecule is also in hydrogen bonding distance 
to Lys269 and Tyr131 (14).  Famoxadone in the Qo binding site is surrounded by 
several aromatic residues, which help to establish a network of aromatic-aromatic 
interactions between famoxadone and the binding site.  The aromatic residues in the 
Qo binding site may play a role in stabilizing the substrate in the binding site and also 
play a role in facilitating electron transfer.  The binding of famoxadone in the Qo 
binding site can be seen in figure 10. 
UHDBT in the Qo binding site
     UHDBT is a benzoquinone derivative and of all the Qo site inhibitors considered, 
UHDBT is the closest structural analog to quinol (Figure 7).  Wedged between 
Pro270 and Val145, is the hydroxyl dioxobenzothiazole moiety of UHDBT.  One 
hydrogen bond is formed between Tyr131 and the O4 hydroxyl group of UHDBT 
(Figure 11).  It is possible that when the extrinsic head domain of ISP is positioned in 
the b-position the protonated His161 of ISP may form a hydrogen bond with the 
carbonyl oxygen O7 of UHDBT.  A deprotonated His161may form a hydrogen bond 




















Stigmatellin in the Qo binding site 
     Stigmatellin is a natural anti-fungal inhibitor produced by myxobacteria S. 
aurantiaca (Figure 7). The binding of stigmatellin in the Qo binding site relies on the  
head domain of ISP being docked in the b-postition (16).  The crystal structure of 
stigmatellin has been solved in several pdb files. In the pdb file 1sqx (2.6 Å 
resolution) the protonated atom NE2 of His161 of ISP forms two hydrogen bonds 
with both the methoxy oxygen (O5) and carbonyl group (O4) of the inhibitor with 
distances of 3.5 Å and 3.4 Å, respectively (12).  A hydrogen bond (2.6 Å) is formed 
between the hydroxyl group O8 of stigmatellin and atom OE2 of Glu271 whose side-
chain undergoes a rotation around chi1 of, ~160o from its native position(12) (Figure 
12).  In a higher resolution (2.1 Å) crystallographic structure of the bc1 complex with 
stigmatellin (pdb code 2a06) His161 of ISP has moved closer to the stigmatellin 
molecule (Figure 13).  The hydrogen bonding distance between the His161 and 
stigmatellin is now 2.68 Å. This difference may be the result of the difference in the 
resolution of the crystal structures. If this were the case then it would be expected that 
the hydrogen bonding distance between Glu271 and stigmatellin would be off also.  
Both crystal structures show about 2.6 Å for this distance.  Therefore, another 
possibility may be that this difference is representative of possible transition states in 
the reaction pathway.  The bc1 complex has the enormous job of coupling electron 
transfer with proton pumping, therefore the entrance and exit of the substrate in the 
active site may require several different geometries of the active site as the reaction 
proceeds from beginning to completion.  Table II shows the correlation of contact 
residues in the Qo binding site relative to the inhibitors.   
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Table II. Qo Binding Site Residues with Inhibitors 
 
____________MOAS  Myzoa  Famoxb UHDBT Stigc 
  
LEU 121  N      I      N       I       I 
MET124  N                      I       I       I       I 
ALA125  N      I       N       I       I 
PHE 128   I                I       I         N       I 
MET129  N     N      N      N       I 
TYR 131      I                           I       I      H      N 
VAL 132      I       I                 N       N      N 
MET 138     N     N       I       I       I 
SER  139      I     N      N      N      N 
TRP  141     N     N                 N                      I      N 
GLY 142      I      I       I       I       I 
ALA 143      I                           I      N      N      N 
VAL 145             N                         I       I       I       I 
ILE   146      I      I      N                      I       I 
ILE   264     N     N                 N                 N       I 
ILE   268      I        N       I       I       I 
LYS  269      I                 I       I                       I       I 
PRO 270      I      I             I                       I       I 
GLU 271     H     H      H      N      H 
TYR 273      I     H       I      N      N 
PHE  274      I      I       I       I       I 
ALA 277     N     N       I       I      N 
TYR  278     N     N         I      N       I 
LEU  281     N     N      N       I      N 
LEU  294            N      I      N      N       I 
ILE   298     N     N       I      N      N 
 
a Abbreviation for myxothiazol  
b Abbreviation for famoxadone 
c Abbreviation for Stigmatellin  
The letter I represents a residue that is close enough to “interact” with the inhibitor as 
revealed in the LIGPLOT representation.  N means that “no” interaction was detected 
in the LIGPLOT representation.  And H represents “hydrogen bonding” as detected in 






The Qi site 
 
     The Qi binding site is positioned at the matrix side of the membrane.  The opening 
of the Qi binding site is inward-facing the opposing monomer.  Shuttling of the 
substrate may be facilitated by the geometric locations of the Qi binding site in one 
monomer with the Qo site in the opposing monomer.  The overall shape of the Qi 
binding site is somewhat like that of a funnel.  The outside of the cavity is wide and 
as you enter into the cavity heading toward the back, the width of the cavity 
decreases.  Residues from helix A, D, and E make up the Qi binding site along with 
part of the propionate side chain of the high-potential heme bH. 
Antimycin A in the Qi binding site 
     Antimycin A is made up of a nine-member puckered dilactone ring in the middle, 
a 3-formylamino salicylic acid (3-FASA) group that is connected to the dilactone ring 
and a hydrophobic tail on the other side of the dilactone ring.  There are two crystal 
structures with slightly different configurations for antimycin A in the Qi binding site 
as revealed in pdb codes 1ntk (2.6 Å) and 1ppj (2.1 Å) (Figure 14 and 15).  The main 
difference appears to be a rotation of the nine-membered puckered dialactone ring.  
This difference may be the result of many different variables.  Crystallization 
conditions between the two data sets are different and may play a role in the rotation 
of the nine-membered dilactone ring.  The overall shape of the two are relatively the 
same where the 3-formylamino salicylic acid group is positioned deep in side the 
back of the Qi binding site, and the nine-membered dialactone ring is positioned more 
towards the outside of the binding site.   
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Figure 15. Antimycin binding in the Qi site (pdb code 1ppj). 
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Ubiquinone binding in the Qi site
     The crystal structure of ubiquinone co-crystallized with the bc1 complex is 
available in pdb files 1sqx (2.6 Å) and 2a06 (2.1 Å) as shown in LIGPLOT 
representation figures 16 and 17 respectively.  Both pdb codes 1sqx and 2a06 have 
ubiquinone modeled in the Qi site where the first two isoprenoid units are attached.  
The head group of the ubiquinone is inserted all the way into the back of the Qi 
binding site cavity.  Geometrically, the ubiquinone head group is oriented with the 
methyl group towards His201.  Atom NE2 of His201 is able to from a hydrogen bond 
with the carbonyl oxygen atom next to the methyl group of ubiquinone.  Phe220 is 
oriented such that aromatic-aromatic interactions are possible with ubiquinone in the 
Qi binding site.  The crystal structures reveal water molecules in the Qi binding site 










































     The protonmotive Q-cycle hypothesis is commonly used to describe the way 
ubiquinol is used twice in proton translocation in the bc1 complex as shown in figure 
18 (17,18).  Q-cycle hypothesis consists of a two substrate binding site model, 
composed of one quinol oxidation (Qo) site and one quinone reduction (Qi) site.  
Bifurcation of electrons comes from a quinol at the Qo site where the first electron is 
transferred through ISP and cytochrome c1 to the soluble electron acceptor 
cytochrome c and the second electron is transferred through hemes bL and bH to the Qi 
site.  Bifurcation of electrons is coupled to the translocation of two protons per 
molecule of quinol.  The oxidized quinol may move to the Qi site to become reduced.  
One complete Q cycle will use two molecules of quinol and one molecule of quinone 
resulting in the production of one quinol molecule along with the translocation of four 
protons to the positive side of the membrane.  After the first crystal structure of the 
bc1 complex was solved it was found that the FeS anomalous signal was diminished, 
this effect was attributed to the mobility of the ISP head domain (8).  Later, 
crystallographic studies revealed the anomalous signal for the FeS cluster in different 












Figure 19.  ISP head domain movement. (A) is the ISPc position, ( C) is the ISPb 




Two noted positions are the position when ISP is docked in the cyt. b cavity noted 
ISPb and the position of the ISP head domain when the FeS has moved to the cyt. c1 
subunit noted ISPc.  As seen in figure 18 when the ISPb configuration is present the 
distance between the FeS and cyt c1 heme is farther away, and when the ISPc 
configuration is present the distance from the FeS to the cyt c1 heme is much closer.  
The first electron that’s given off in the Qo site as described by the Q cycle is 
transferred to FeS in the ISPb configuration.  It was noted in the first solved crystal 
structure that this distance between FeS and cyt c1 heme in ISPb configuration was too 
far for efficient transfer of the electron from FeS to cyt c1 heme (8), so it was 
postulated that it is necessary for the ISP head domain to move to the ISPc 
configuration in order to allow for the transfer of the electron from FeS to the cyt c1 
heme.  Very well crafted site directed mutagenesis studies provided further evidence 
to support the notion that mobility of the ISP head domain is needed for proper 
functioning of the bc1 complex.  It was found that when the region of ISP between the 
head domain and the membrane bound alpha helix in Rhodobacter sphaeroides 
termed the “neck region” was made more rigid by inserting cysteines to create a 
disulfide bridge or when neck region residues were mutated to prolines, there was a 
diminishment of the bc1 complex activity (20,21).  Further mutagenesis studies on 
ISP and cyt. b subunits in Rhodobacter sphaeroides, where a double mutant 
[A185C(cyt. b)/K70C(ISP)] was generated to determine whether the head domain 
movement in  head domain of ISP is essential for activity in the bc1 complex.  This 
double mutant is placed on cyt. b and the ISP head domain in a location where the 
ISP head domain and cyt. b come in contact in the ISPb configuration.  The double 
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mutant revealed that when the di-sulfide bond is formed between the ISP head 
domain and cyt. b (causing the ISP head domain to lock in a fixed position), a 
diminishment of activity in the bc1 complex in Rhodobacter sphaeroides was 
observed (22).  Similar site directed mutagenesis studies confirmed the bc1 complex 
functions as a dimer in solution (23).   The combination of x-ray crystallographic 
structural data and site directed mutagenesis studies provide strong evidence for the 
importance of the mobility of the ISP head domain in the functioning of the bc1 
complex. 
  Prior to the first crystal structure of the bc1 complex, the study of various 
inhibitors of the bc1 complex played an important role in elucidating the mechanics of 
the bc1 complex (24,25).   In spite of intense efforts by many investigators none of the 
crystal structures of the bc1 complex show ubiquinol or ubiquinone in the Qo site as 
predicted by the Q-cycle.  However, some of the crystal structures show various non-
competitive inhibitors in the Qo site. 
 Another mechanism to describe the functioning of the bc1 complex has been 
purposed that consists of the electron taking a linear path from quinol -> bL -> bH -> 
FeS -> c1 (Figure 20) (26).  This linear path mechanism is based off of the 
observations that in the presences of P side inhibitors myxothiazol, MOA-stilbene, 
stigmatellin or N-side inhibitor antimycin added to bovine-heart submitochondrial 
particles (SMP) pretreated with ascorbate and KCN to reduce the high potential 
components (FeS and cyt c1 heme) of Complex III, addition of succinate reduced 




Figure 20. Linear mechanism.  Where N is the matrix side and P is the intermembrane 
















This is an indication that if the high potential chain (FeS and cyt c1) were already 
reduced then the addition of succinate which would cause Complex II to generate a 
molecule of quinol, and the quinol would then cause the reduction of bH in complex 
indication that the first redox group to be reduced in this case is heme bH contrary to 
the Q-cycle hypothesis which states that the first redox group to get reduced is the 
FeS.  The linear path mechanism is also based of the observation the reverse electron 
transfer from ISP reduced with ascorbate plus phenazine metho-sulfate to cytochrome 
b in ubiquinone depleted SMP and ubiquinone replenished SMP revealed that Q was 
not required for electron transfer from ISP to b, a reaction that was inhibited by 
antimycin (26).  The reverse electron transfer experiment is used to argue the lack of 
the need for a quinone or quinol molecule to allow for the flux of electron flow 
between cyt. b and the high potential chain as described in the proton-motive Q cycle, 
which would support the conclusion that the electron travels from the heme bL -> FeS 
-> c1.  The linear path mechanism also operates off the study that shows that 
antimycin did not inhibit electron transfer from bH to ubiquinone, which significantly 
deviates from the Q-cycle mechanism (26).  Several crystal structures show antimycin 
binding in the Qi site; if antimycin does not inhibit electron transfer from bH to 
quinone then it is possible that an additional binding site for the ubiquinol or 








It is important to note that the protonmotive Q-cycle hypothesis was developed 
before the first crystal structure of the bc1 complex was solved, which would have 
allowed for a more effective analysis of the geometry of the active sites.   Considering 
the resources available at the time of the development of the protonmotive Q-cycle 
hypothesis, it is astounding to see the predictive power of the Q-cycle hypothesis in 
effect, now that structural data is available.    The Q-cycle hypothesis adequately 
describes a mechanism for a two separate substrate binding site model in a 
monomeric bc1 complex, and these two separate binding sites are also confirmed 
from the crystal structures with inhibitors for the Qo and Qi sites.  However, there 
have not been any experiments to rule out the possibility of more than two binding 
sites for the substrates in the bc1 complex.  Several studies have opened the door to 
the recognition of additional substrate binding sites in the bc1 complex.  An intriguing 
study that was ahead of the studies on the bc1 complex at its time and before the first 
crystal structure of the bc1 complex was solved is the 3-azido-2-methyl-5-methoxy-6-
(3,7-dimethyloctyl)1,4-benzoquinone (azido-Q) labeling studies which confirmed the 
existence of more than two binding sites in the bc1 complex (27).  A study using 
nuclear magnetic resonance (NMR) recognizes that three molecules of the substrate 
bind to the bc1 complex (28).  Thus, in order to understand how the bc1 complex 
functions correctly, it is critical to have a detailed understanding of the correct 
number and location of binding sites for the substrates.  X-ray diffraction experiments 
with 2,3,4-trimethoxy-5-decyl-6-methyl-phenol (TMDMP) revealed extremely weak 
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binding in a third binding site.  In order to unambiguously detect and confirm this 
third binding site 2-Bromo-5,6-dimethoxy-3-pentyl-benzene-1,4-diol (2BrQ), a 
quinol analogue with bromine substituted in place of the methyl group on quinol, was 
synthesized.. The bromine anomalous signal in the x-ray diffraction data will be used 
to allow for the detection of the position and orientation of the active quinol analog.  
X-ray diffraction data is collected at a wavelength slightly above the bromine edge to 
allow for the detection of the bromine anomalous signal in the x-ray diffraction data.  
Preliminary kinetics studies show 2BrQ initially active in the bc1 complex at lower 
concentrations and inhibition of the bc1 complex at higher concentrations.  X-ray 
crystallographic analysis of the bc1 complex crystals prepared with 2BrQ show an 
anomalous signal for the bromine in a third substrate binding site separate from the Qi 
and Qo sites described in the Q-cycle model.  This binding site is located in the same 
region as revealed by azido-Q labeling experiments (27).  When 2BrQ is combined 
with 2-(10-Bromo-decyl)-5,6-dimethoxy-3-methyl-benzene-1,4-diol (QC10Br) in bc1 
complex crystals the anomalous signal for the 2BrQ shows up in a new third Qm 
binding site and the QC10Br is detectable in the Qo site.  Identifying the 2BrQ 
molecule in the Qm binding site allows for an understanding of the binding sequence 
of substrates in the bc1 complex due to the 2BrQ binding properties in the when the 
bcl complex is oxidized verses reduced, where the oxidized bc1 complex would be the 
state of the enzyme in the beginning of the reaction mechanism.  The x-ray 
crystallographic analysis of the 2BrQ molecule in conjunction with other studies 
allows for the deciphering of the most probable electron transferring pathways 
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X-ray Diffraction Analysis of TMDMP, a Non-oxidizable 



















The bc1 complex in the electron transfer chain plays a critical role in the 
production of energy for aerobic cells.  The currently accepted proton motive Q-cycle 
hypothesis is used to describe the catalytic mechanism for the bc1 complex.  The Q-
cycle purposes two binding sites.  The two binding sites are the Qo site, for the 
oxidation of quinol, and the Qi binding site, for the reduction of quinone.  The 
location of the Qo site is currently the same location as known non-competitive 
inhibitors like stigmatellin.  To determine a more accurate depiction of the Qo site, 
TMDMP was synthesized.  TMDMP is a competitive inhibitor that is structurally 
similar to quinol and we are able to detect the position of TMDMP in a third binding 
site.  By mimicking the reducing effect of quinol on the bc1 complex with TMDMP, 
three different binding states for TMDMP were revealed.  By using a highly 
structurally similar substrate analog in combination with the injection of electrons 
into the complex, allowed for the ability to follow important substrate positions in the 
complex by the use of macromolecular x-ray crystallography, which has proven in 
this case to be a desired alternative when time-resolved crystallography techniques 
are not feasible.  From these results a dual quinol oxidation site Q-cycle mechanism 








Ninety percent of the energy needed for aerobic cells comes from the 
mitochondria respiratory chain by way of ATP synthesis.  The respiratory chain 
contains four electron transfer complexes and an ATP synthase (1).   Ubiquinol-
cytochrome-c oxidoreductase (bc1 complex) is a dimeric transmembrane protein that 
is the central segment of the respiratory chain in the mitochondria.  The bc1 complex 
oxidizes ubiquinol and reduces cytochrome c with concomitant generation of a proton 
gradient and membrane potential for ATP synthesis by ATP synthase (2). 
The mitochondria bc1 complex is a dimer with a molecular mass of about 500 kDa.  
Three subunits out of eleven total subunits are essential for electron transfer.  The 
three essential subunits are cytochrome b which contains a total two b-type hemes (bl 
and bh ), cytochrome c1 which contains a c-type heme, and iron-sulfur protein (ISP) 
which contains a 2Fe-2S (FeS) cluster.   
The protonmotive Q-cycle hypothesis is commonly used to describe the way 
ubiquinol is used twice in proton translocation in the bc1 complex (3,4).  The Q-cycle 
hypothesis describes two substrate binding sites, a quinol oxidation (Qo ) site and a 
quinone reduction (Qi) site.  Bifurcation of electrons comes from a quinol at the Qo 
site where the first electron is transferred through ISP and cytochrome c1 to the 
soluble electron acceptor cytochrome c and the second electron is transferred through 
hemes bL and bH to the Qi site.  The bifurcation of electrons is coupled to the 
translocation of two protons per molecule of quinol.  The reduced quinol may move 
to the Qi site to become oxidized.  One complete Q cycle will use two molecules of 
 46
quinol and produce one quinol molecule along with the translocation of four protons 
to the positive side of the membrane. 
The first crystal structure of cytochrome bc1 complex from bovine heart 
mitochondria was solved at 2.9 Å resolution in 1997 (5).  A year later more complete 
structures were reported (6-8).  None of the crystal structures of the bc1 complex 
show quinol or quinone in the Qo site.  However, some of the crystal structures show 
various non-competitive inhibitors in the Qo site (9).  The key feature of the Q-cycle 
mechanism is the initial bifurcation of electrons from ubiquinol in the Qo site.  Thus, 
in order to understand how the bc1 complex functions correctly, it is critical to have a 
detailed understanding of the correct binding site/sites of the substrate.  
In order to locate the initial binding site for quinol, 2,3,4-Trimethoxyl-decyl-methyl-
phenol (TMDMP) was synthesized and kinetic studies show TMDMP to be a 
competitive inhibitor as opposed to the non-competitive inhibitors previously used to 
define the initial quinol binding site (10).  TMDMP is almost identical to quinol 
except for the substitution of a methoxy group in place of the hydroxyl group as 
shown in figure 1.  Because TMDMP is a competitive inhibitor and is highly 
structurally similar to ubiquinol, the TMDMP binding site should provide compelling 
evidence for the initial binding site of ubiquinol.  We are able to detect the TMDMP 
binding site by x-ray crystallography.  The initial binding site for this competitive 
inhibitor is different from the binding site of the other inhibitors.  This initial binding 
site of TMDMP will be referred to as Qm, the “m” is used to indicate middle.  The Qm 
binding site is located more toward the middle of the membrane relative to the Qo and 
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Qi sites.   The detection of the possible initial substrate binding site will allow for a 














































MATERIAL AND METHODS 
 
 Protein preparation and crystallization.  
       The bc1 complex from bovine heart mitochondria was prepared as described 
previously (5,11). For crystallization, the bc1 particles were subject to an additional 
15-step NH4Ac fractionation to remove impurities; pure bc1 complex in the oxidized 
form was recovered from the precipitates formed between 18.5% and 33.5% NH4Ac 
saturation; and the final product was dissolved in 50 mM Tris-HCl buffer, pH 7.8, 
containing 0.66 M sucrose to a protein concentration of 30 mg/ml and frozen at -80 
˚C until use. The concentrations of cyt. b and c1 were determined spectroscopically, 
using millimolar extinction coefficients of 28.5 and 17.5 for cyt. b and c1, 
respectively. The homogeneity in redox state of bc1 was confirmed 
spectrophotometrically.  
 Purified bc1 complexes were adjusted to a final concentration of 20 mg/ml in a 
solution containing 50 mM MOPS buffer at pH 7.2, 20 mM ammonium acetate, 20% 
(w/v) glycerol, and either 0.1% of decanoyl-N-methylglucamide or 0.1% of 
diheptanoyl phosphatidylcholine or 0.16% sucrose monocaprate.  Native crystals 
were grown in either sitting or hanging drops and appeared in 3-4 weeks. The 
TMDMP bound bc1 crystals were grown under similar conditions except that a five-
fold in molar excess of TMDMP was added to the protein solution prior to 
crystallization. Both native and TMDMP bound bc1 crystals had a rectangular shape 
ranging in sizes from 0.4 to 0.7 mm, and were cryo-protected at a glycerol 
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concentration of 30-40%. The TMDMP bound crystals had the same space group and 
similar unit cell dimensions to that of native crystals. 
X-ray diffraction data collection and reduction.  
    Crystals were stable at synchrotron radiation sources when cryo-cooled to 100 K, 
allowing collection of complete data sets. Data were collected at beamlines IMCA-
CAT and SBC-CAT of the Argonne Photon Source at Argonne National Laboratory 
in Argonne IL., with a wavelength of 1.0 Å. Raw diffraction data were processed with 
DENZO, and integrated intensities were merged and scaled with SCALEPACK, both 
are part of the HKL program package (12).   
Data analysis, structure refinement and modeling.  
 The CNS software package (13) were used for merging and scaling different data 
sets, calculating structure factors from atomic models, density modifications and 
computing Fourier maps. The atomic coordinates of the native bc1 (5)(8) were used to 
initially phase the data followed by rigid body refinement. Xfit (14), Molscript  and 










RESULTS AND DISCUSSION 
 
TMDMP binding in oxidized bc1 complex crystals  
 The bc1 complex inhibitor binding sites are located in the cytochrome b subunit.  
Cytochrome b consists of eight transmembrane helixes that are labeled sequentially 
from A to H starting from the N-terminus.  Currently, there are only two binding sites 
used to describe the Q-cycle mechanism. One of the binding sites is the quinol 
oxidation site, located where the inhibitor stigmatellin binds and the other is the 
quinone reduction site located where the inhibitor antimycin binds.  The initial 
binding site for TMDMP is located in a third binding site separate from the two 
binding sites used to describe the Q cycle mechanism.  The initial binding site for 
TMDMP, in mostly oxidized bc1 complex crystals, became visible in a difference 
electron density map (FoTMDMP – FoNative 3.7 Å) and shows a 6.85 sigma peak for 
TMDMP in the third binding site labeled Qm and no detectable peaks show up in the 
Qo site.  The position of TMDMP in the Qm site relative to the position of stigmatellin 
and antimycin in the Qo site can be seen in figure 2.  This mostly oxidized binding 
state will be referred to as T1.  Residues (F325, W326, V329, L333 and T336) of 
helix G and residues (M96, Y95, and I92) of helix D surround the cavity opening for 
the Qm binding site.  The interior of the Qm binding site is defined by residues (Y358, 
I362, L332, L328) on the right side of the cavity, residues (Y195, L120, V98) on the 
left side of the cavity, residue (F276) on the top of the cavity, residues (I304, L102) 
on the bottom of the cavity and residue (L301) located deep in the interior back of the 





















































Figure 2.  Inhibitors and difference map density in the T1 state.  The density is 




Preliminary molecular modeling analysis alludes to the possibility of hydrogen 
bonding between Y358 and the substrate (Figure 3).  The position of TMDMP is 
closer to heme bH (about 7.02 angstroms to atom CBC on heme bH) than it is to heme 
bL (about 15.96 angstroms to the CBC atom on heme bL).  TMDMP density is about 
25 angstroms away from the FeS cluster position when the FeS cluster is in the 
position directly above cytochrome b or the "b-position".    Since we see the initial 
binding of TMDMP, a competitive inhibitor, closest to heme bH, it is possible that 
heme bH would receive the first electron from quinol in this binding site.  
TMDMP binding in reduced bc1 complex crystals 
 From the oxidized crystals we are able to determine the initial binding site 
location for TMDMP.  One very important property of quinol is its ability to reduce 
the bc1 complex.  In order to investigate what happens after quinol enters the Qm site, 
it is important to simulate the reducing effect that quinol has on the bc1 complex after 
it enters the Qm site. By employing a technique where bc1 crystals with TMDMP were 
reduced either before or after crystal growth, allowed for the ability to simulate the 
reducing effect that quinol has on the bc1 complex.  By reducing crystals after crystal 
growth, we are able to take advantage of the greatly diminished rotational and 
translational degrees of freedom of the bc1 complex, which may affect a weakly 
binding intermediate.  Reduction after crystal growth also has an effect on the FeS 
occupancy. These characteristics appear to have significant ramifications on the 
binding affinity properties of TMDMP and reveal important insights into the quinol 


























































 Mostly oxidized bc1 crystals were grown with excess TMDMP, then after crystal 
growth the oxidized crystals were then soaked with ascorbate, at 4 times cytochrome 
c concentration, to reduce the crystals.  Surprisingly, a difference electron density 
map (FoTMDMP – FoNative 3.6 Å) reveals the binding of three TMDMP molecules.  
There are two peaks in the Qm site with sigma values of 5.65 and 6.60 and one peak 
in the Qo site at 5.61 sigma (Figure 4).  We shall refer to this binding state as T2.  It 
appears from the peak height values for the Qm site that the molecule representing the 
5.65 peak has a weaker affinity for the binding site.  This is in agreement with the 
notion of a strong binding (QoS) and weak binding (QoW) substrate (21).  Interestingly 
enough the QoS peak is closer to Y358, alluding to the possibility that the hydrogen 
bonding with the hydroxyl group of Y358 may account for the stronger binding 
affinity.  The two TMDMP molecules in the Qm site are clearly resolved in a 5 sigma 
contoured density map as seen in figure 5.  The residues surrounding the peak in the 
Qo site are V145, I146, L149, I268, P270, F274, Y278, L281 and L294.  The peak 
that resides in the Qo site appears to overlap the position of stigmatellin and other Qo 
site inhibitors (Figure 6).  We see from the position of the peak that Y278 may play a 
role in parallel-displaced pi stacking interactions with the substrate. Parallel-displaced 
pi stacking interactions are interactions that involve pairs (dimers) of aromatic rings 
in an off-centered parallel orientation.  Aromatic-aromatic interactions have been 








































































































































































When the reduction occurred before crystal growth of the bc1 complex and 
TMDMP, a difference electron density map [FoTMDMP – FoNative 4.5 Å] shows a 5.9 
sigma peak in the Qo site and density less than 2 sigma in the Qm site.  This state will 
be referred to as T3.  It seems probable that the increased rotational and translational 
degrees of freedom for the bc1 complex may be necessary to facilitate the release of 
the Qm site molecules.  In the Qo site we see that the peak has moved farther inside 
the site somewhat overlapping the other ring moiety of stigmatellin (Figure 7). A 
comparison of TMDMP in the Qo site for T2 and T3 can be seen in figure 8.  It may be 
possible that each of the ring moieties of stigmatellin may indeed represent important 
transition state positions for the substrate.  Solid state NMR studies using 13C-labelled 
quinone, show that the binding of myxothiazol (a Qo site inhibitor) allowed for the 
displacement of ~ 2.28 mole of quinone / mole bc1 (16).  This was however attributed 
to the hypothetical and remote possibility of myxothiazol having weak affinity for the 
Qi site.  It may be possible that myxothiazol displaced the quinone in the Qo site and 
the Qm site.  Stigmatellin was shown to displace close to two quinone molecules, 
which may have been the quinone in the Qo site and Qm site.  Photo-affinity labeling 
experiments are also in agreement with the Qo and Qm sites.  Photo-affinity labeling 
using [3H]azido-Q shows labeling on two sites, residues 326-336 which would 
correspond to the Qm cavity and residues 142-155 which would correspond to the Qo 
cavity (17).  The position of these two photo-affinity labeled sites relative to TMDMP 




















































































Figure 8.  Comparison of  T2 (green) and T3 (blue) in the Qo site.  To outside of the 












































Figure 9. Azido Q Labeling.  Red density is T2 difference map contoured at 5 sigma.  







FeS occupancy in oxidized vs. reduced
 The iron sulfur cluster occupancy in the T1 state appears to be significantly 
diminished relative to the T3 state where we observe a stronger signal.  It has been 
shown previously from native bc1 complex crystals that the occupancy of the FeS 
cluster in the b position is sensitive to the reduction state of the bc1 complex from 
anomalous peak height measurements (18).  To calculate the normalized FeS cluster 
peak height we divided the peak height of the FeS cluster by the peak height of the Fe 
atom in heme bH.  For the T1, T2 and T3 crystals we see normalized peak heights of 
0.309, 0.392 and 0.533 respectively for the FeS cluster.  In the T3 crystal it may be 
that both cytochome c1 is reduced and heme bH is slightly reduced.  The FeS 
anomalous peak heights indicate that when the substrate initially binds to the oxidized 
bc1 complex in the T1 state, the iron sulfur cluster has a very low occupancy in the b-
position.     
Proton motive Q cycle 
 The essential backbone of the current Q cycle is the initial bifurcation of electrons 
upon the entry of the first molecule of quinol into the active site of the bc1 complex.  
The first electron is hypothesized to go to the high potential iron sulfur cluster and the 
second electron going to the low potential heme bL.  The initial reduction of heme bH 
has previously been purposed where the electron would take a linear path from quinol 
-> bH -> bL -> ISP -> c1 (19).  This linear path however would not take into account 
the T2 and T3 states where you could have direct electron transfer to ISP from quinol 
thus bypassing hemes bH and bL.  By being able to see the T1, T2, and T3 states a dual 
quinol oxidation site Q cycle model may be purposed.  From the T1 state we see that 
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it is likely that heme bH is reduced first and interestingly enough, located in the Qm 
binding site in the yeast bc1 complex (pdb code 1ezv) is a crystallographic defined 
water molecule adjacent to Y359 in yeast cytochrome b subunit, which corresponds 
to Y358 in bovine.  This water molecule appears to be the only water molecule 
assigned in the middle of the membrane, considering the interior of the membrane is 
indeed hydrophobic it seems plausible that this water molecule may play a role in the 
reaction mechanism in the Qm site.   
In summary, a viable catalytic mechanism may actually be a combination of 
linear and bifurcation electron transfer steps.  Where the linear step would occur 
before the bifurcation step, since the Qm site is closer to heme bH.  Crystallographic 
refinement and site directed mutagenesis research is in progress to provide a detailed 
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The Detection and Conformation of a Hidden Substrate Binding 
Site in the bc1 Complex by the Use of X-ray Crystallographic 


















The bc1 complex is an integral component of the electron transfer chain 
responsible for aiding in the production of a proton gradient for ATP synthesis.  
Mutations in the bc1 complex are associated with epilepsy and other human diseases.  
Functioning of the bc1 complex is commonly explained by the well known proton 
motive Q cycle.  The proton motive Q cycle hypothesis makes use of only two 
completely separate substrate binding sites in the bc1 complex.  Crystallographic 
anomalous signal tracking allowed for the deciphering of a hidden third substrate 
binding site which may have possible implications on the electron transferring 
















The electron transfer chain is one of the most exciting aspects of the metabolic 
process that is essentially important for the aerobic metabolic process.  Four electron 
transfer complexes and an adenosine tri-phosphate (ATP) synthase complex make up 
the electron transfer chain, which efficiently generates about ninety percent of the 
energy needed for survival of the organism.  Mitochondrial ubiquinol cytochrome c 
oxido-reductase (bc1 complex) is the central components of the electron transfer chain 
in the mitochondria.  Mutations in the cytochrome bc1 complex have been found to be 
related to human diseases (1-4).   
 The bovine mitochondrial bc1 complex is a dimeric transmembrane protein that 
consists of 11 subunits with a dimeric molecular weight of about 500 kDa (5).  An 
intricate electron transfer pathway is used by the bc1 complex to oxidize ubiquinol 
and reduces cytochrome c with the concomitant generation of a proton gradient and 
membrane potential for ATP synthesis by ATP synthase.  Three subunits out of the 
eleven total subunits are essential for electron transfer in complex III.  The three 
essential subunits are cytochrome b which contains low and high potential b-type 
hemes (bl and bh), cytochrome c1 which contains a c-type heme, and the iron –sulfur 
protein (ISP) which contains a 2Fe-2S (FeS) cluster. 
The protonmotive Q-cycle hypothesis is commonly used to describe the way 
ubiquinol is used twice in proton translocation in the bc1 complex (6, 7).  Q-cycle 
hypothesis consists of a two substrate binding site model, a quinol oxidation (Qo ) site 
and a quinone reduction (Qi) site.  Bifurcation of electrons comes from a quinol at the 
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Qo site where the first electron is transferred through ISP and cytochrome c1 to the 
soluble electron acceptor cytochrome c and the second electron is transferred through 
hemes bL and bH to the Qi site.  Bifurcation of electrons is coupled to the translocation 
of two protons per molecule of quinol.  The oxidized quinol may move to the Qi site 
to become reduced.  One complete Q-cycle will use two molecules of quinol and one 
molecule of quinone resulting in the production of one quinol molecule along with 
the translocation of four protons to the positive side of the membrane.  Prior to the 
first crystal structure of the bc1 complex, the study of various inhibitors of the bc1 
complex played an important role in elucidating the mechanics of the bc1 complex (8, 
9).  The first crystal structure of cytochrome bc1 complex from bovine heart 
mitochondria was solved at 2.9 Å resolution (10).  Afterwards, more complete bc1 
complex structures were reported (11-13).  In spite of intense efforts by many 
investigators none of the crystal structures of the bc1 complex show quinol or quinone 
in the Qo site as predicted by the Q-cycle.  However, some of the crystal structures 
show various non-competitive inhibitors in the Qo (9).   
It is important to note that the protonmotive Q-cycle hypothesis was developed 
before the first crystal structure of the bc1 complex was solved, which would have 
allowed for a more effective analysis of the geometry of the active sites.   Considering 
the resources available at the time of the development of the proton motive Q-cycle 
hypothesis, it is astounding to see the predictive power of the Q-cycle hypothesis in 
effect now that structural data is available.    The Q-cycle hypothesis adequately 
describes a mechanism for a two separate substrate binding site model in the bc1 
complex, and these two separate binding sites are also confirmed from the crystal 
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structures with inhibitors for the Qo and Qi sites.  However, there have not been any 
experiments to rule out the possibility of more than two binding sites for the 
substrates in the bc1 complex.  A study using NMR methods recognizes that three 
molecules of the substrate bind to the bc1 complex (14).  Azido-Q labeling studies 
also reveal the existence of more than two binding sites in the bc1 complex.  Thus, in 
order to understand how the bc1 complex functions correctly, it is critical to have a 
detailed understanding of the correct number and location of binding sites for the 
substrates.  In order to unambiguously detect and confirm this third binding site an 
active quinol analog was synthesized with a bromine atom substituted in the place of 
the methyl group on the quinol ring.  The bromine will serve as the anomalous signal 
tracing device to allow for the detection of the position and orientation of the active 
quinol analog.  X-ray diffraction data was collected at a wavelength slightly above the 
bromine edge to allow for the detection of the bromine anomalous signal in the x-ray 
diffraction data.  Preliminary kinetics studies show 2-Bromo-5,6-dimethoxy-3-pentyl-
benzene-1,4-diol (2BrQ) initially active in the bc1 complex and at higher 
concentrations 2BrQ will start inhibiting the bc1 complex.  X-ray crystallographic 
analysis of the bc1 complex crystals prepared with 2BrQ show an anomalous signal 
for the bromine in a third substrate binding site separate from the Qi and Qo sites 
described in the Q-cycle model.  This binding site is located in the same region as 
revealed by azido-Q labeling experiments (15).  When the 2BrQ is combined with 2-
(10-Bromo-decyl)-5,6-dimethoxy-3-methyl-benzene-1,4-diol (QC10Br) in bc1 
complex crystals the anomalous signal for the 2BrQ shows up in a new third binding 
site and the QC10Br is detectable in the Qo site.     
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MATERIALS AND METHODS 
 
Mitochondrial bc1 complex crystal growth 
Cytochrome bc1 complex from the bovine heart mitochondria was prepared as 
previously reported (16,17).  To remove impurities and enhance crystallization of the 
bc1 complex, bc1 particles are subjected to an additional 15-step ammonium acetate 
fractionation.  Pure bc1 complex is recovered from precipitates formed between 
18.5% and 33.5% ammonium acetate saturation; the pure bc1 complex is then 
dissolved in 50 mM Tris-HCl buffer, pH 7.8, containing 0.66 M sucrose to a protein 
concentration of  ~30mg/ml and stored at -80oC until used for crystallization.  
Concentrations of cyt c1 and cyt b are determined spectroscopically, using millimolar 
extinction coefficients of 17.5 cm-1 mM-1 and 28.5 cm-1 mM-1 respectively. 
 For crystallization the frozen solutions of purified bc1 complexes were allow to 
thaw on ice and were then adjusted to a concentration of ~ 18mg/ml in a buffer of 50 
mM Mops at pH 7.2, 20 % (v/v) glycerol, 20 mM ammonium acetate, and 0.16% 
(w/v) sucrose monocaprate.  For co-crystallization experiments 2BrQ analogues were 
added to bc1 complex samples that were either partially reduced where cyt c1 was 
~18% reduced or the bc1 complex sample was pre-oxidized with ferricynite before the 
addition of 2BrQ.  Then the solution was allowed to sit over night at 4oC and sitting 
drop plates from Hampton were set up using 30uL of solution in the sitting drop and 
100uL of equilibrating solution in the well.  The crystallization setup is also described 
in previous publications (10, 16).  Crystals appeared in two weeks and the sizes of the 
crystals ranged from 0.3mm to 1.2mm.  To prevent the formation of ice build-up on 
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the crystals when the crystals are frozen, the crystals were cryo-protected at a glycerol 
concentration of 33% (w/v). 
X-ray diffraction data collection and reduction 
 Complete sets of data were obtainable at synchrotron radiation sources when 
cryocooled to 100K.  To optimize the bromine anomalous scattering signal, data was 
collected at around 0.907 angstroms slightly below the bromine absorbance edge in 
angstroms of (0.9202 angstroms).  All of the data used in this work was collected at 
the Advance Photon Source, Argonne National Laboratory on the 17-ID IMCA-CAT 
beam line.  Raw diffraction data was processed with Mosflm, and integrated 
intensities were merged and scaled with SCALA which are part of the CCP4 package 
(18-20). 
Data analysis and structure refinement 
Structure refinement for the data was carried out with the REFMAC program 
(21).  The starting atomic coordinates of the native bc1 complex were used for the 
initial phasing of the model followed by rigid body, iterative maximum likelihood 
and TLS (translation, libration, and screw tensor) refinement.  Between refinement 
sigma A weighted 2Fo-Fc, Fo-Fc, and anomalous difference maps were calculated 
and used in the program Xfit from the XtalView package where model corrections 
were made (22).  Atomic models for the substrates were generated in the CCP4 





RESULTS AND DISCUSSION 
 
Conformation of an Active Qm Binding Site 
2BrQ is initially active in the bc1 complex and at higher concentrations 2BrQ will 
start inhibiting the bc1 complex.  Reduced 2BrQ is still capable of passing electrons to 
the bc1 complex, and at higher concentrations 2BrQ will start inhibiting the bc1 
complex.  This intrinsic property of 2BrQ will allow for the ability to decipher details 
of the initial reduction of the bc1 complex once the location and position of this 2BrQ 
is resolved in the bc1 complex crystal structure.  When the number of carbon atoms in 
the alkyl substituent on the 2BrQ is decreased there is an observed decrease in the 
enzymatic activity of the bc1 complex.  This decrease in activity proved to be a 
powerful property in allowing for the detection of the 2BrQ molecule in the 
diffraction data.  Initial attempts to co-crystallize 2-Bromo-5,6-dimethoxy-3-decyl-
benzene-1,4-diol (2BrQ10) did not yield significant peaks in the anomalous difference 
map; however the use of 2BrQ was successful.  It seems the lower activity of the 
2BrQ may be related to the ability of  2BrQ to spend more time in the binding site 
versus the time spent in the binding site of 2BrQ10 thus allowing for its detection in 







2BrQ confirms existence of a third substrate binding site 
To determine where the initial binding site of 2BrQ binds, oxidized crystals were 
soaked with 2BrQ.  X-ray diffraction data was collected at a wavelength slightly 
above the bromine edge to allow for the definitive unambiguous detection of 2BrQ in 
the bc1 complex.  An anomalous difference map was calculated and a (5 sigma) 
anomalous peak for the bromine was detected in the Qm binding site (Figure 1). The 
FeS anomalous signal was diminished significantly, which has been shown to 
represent the oxidized state of the enzyme (17).  From the difference map (Fo-Fc) it 
appears that the hydroxyl group on the 2BrQ is hydrogen bonding with the (backbone 
carbonyl oxygen atom of residue of Ser 297) suggesting a possible mode of catalytic 
action in this third substrate binding site for the removal of the 2BrQ hydroxyl 
hydrogen atom.  The 2BrQ molecule is 9.54 angstroms from the edge of heme bH and 
15.70 angstroms from the edge of heme bL and 20.13 angstroms from the iron sulfur 
cluster.  This data also reveals the binding of the native substrate ubiquinol in the Qo 
site and ubiquinol with 2 isoprene groups in the Qi site (Figure 2,3).  The Fo-Fc 
difference map revealed enough map density to allow for the modeling in of all ten 
isoprene groups as seen in figure 2. 
2BrQ + QC10Br Co-Crystallization 
 In order to determine whether the binding of the 2BrQ in the Qm site might 
have an effect on the ability of quinol to bind in the Qo site 2BrQ and 2-(10-Bromo-
decyl)-5,6-dimethoxy-3- methyl-benzene-1,4-diol (QC10Br) was co-crystallized with 
the oxidized bovine bc1 complex and x-ray diffraction data were collected slightly 





Figure 1. 2BrQ binding in the Qm site.  The anomalous difference map is in red 












Figure 2. Qo site native ubiquinol with ten isoprene groups modeled in.  The blue 
density is five sigma contoured Fo-Fc density.  Red density is for the anomalous 























 Anomalous and Fo-Fc difference maps were calculated for the 2BrQ+QC10Br 
data set.  The anomalous map show a five sigma peak the binding of 2BrQ in the Qm 
site and 4 sigma anomalous peak for the bromine on the end of the alkyl chain on 
QC10Br  (Figure 4).  In this data set the 2BrQ molecule has rotated 180 degrees, 
relative to the position of the 2BrQ in the other data set.  This rotation is interesting in 
that it now places the same hydroxyl group in hydrogen bonding range of the 
carbonyl oxygen of residue Ser297.  And the anomalous signal for the FeS is stronger 
indicating the bc1 complex in a more reduced state.  In figure 5, QC10Br is observed 
in the Qo site with the anomalous difference map density for the bromine at the end of 
the ten carbon chain. 
Conclusion 
The combination of information gained from these two data sets allow for the 
explanation of a possible Q-cycle mechanism where only one ubiquinol is needed per 
turnover.  As shown in figure 5, in step one the substrate would arrive in the Qm 
binding site due to the fact that the Qm site is the most outward facing cavity  and the 
most easily accessible cavity of the three from the outside of the bc1 complex figure.  
From the Qm site the substrate will pass two electrons to cytochrome b thus reducing 
cytochrome b which is inline with the oxidant induce experiments.  In the next step a 
oxidized ubiquinone molecule from the Q-pool will come into the Qi site and pick up 
both electrons from cytochrome b and pick up two protons from the matrix.  This step 
is directly inline with the oxidant induce experiments which initially show the 







Figure 4. (A) 2BrQ binding in Qm site with the anomalous signal for the bromine 
rotated 180 degrees.  (B) QC10Br binding in the Qo site.  In green is the ISP subunit 





















Figure 5.  Schematic illustration of a possible Q-cycle mechanism.  The letter (A) 










In the third step, the now reduced quinol in the Qi site will now move to the Qo site of 
the other monomer and now bifurcate electrons one to FeS and one to heme bL.  In 
the next step the electron that went to heme bL will transfer to heme bL on the 
opposing monomer and in the last step transfer the electron to heme c1 by passing the 
FeS cluster to complete one turnover of the bc1 complex from one quinol molecule.   
Thus the study of this 2BrQ provides an enormous advantage over the other 
inhibitors used to understand how the bc1 complex functions due to the fact that 2BrQ 
is initially active in the bc1 complex and retains all the features of the quinol head 
group except for the methyl group substitution with bromine.  Most of the inhibitors 
used in the development of the Q-cycle are not capable of reducing the bc1 complex 
and many of the inhibitors in the Qo site exhibit non-competitive inhibition thus 
making the understanding of how the actual substrate binds extremely complicated.  
2BrQ offers a significant advantage, in that the identity and orientation of the 
compound can be easily detected in x-ray crystallographic data unambiguously by 
collecting anomalous data for the bromine atom.  These results provide a compelling 
argument for the existence of a functional third substrate binding site in the 
cytochrome bc1 complex.  The Qm binding site appears to be the point where the first 
quinol molecule comes in to reduce the bc1 complex, thus the closest redox goup 
would be the cytochrome b bH heme.  And the Qo site seems to be the where the 
second quinol comes in to reduce the FeS.  The stoichiometry of the Q-cycle stays the 
same in that two quinol molecules reduce the bc1 complex and one molecule of quinol 
is generated per turnover, however in this revised mechanism the quinol that is 
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generated is used as opposed to the quinol leaving the bc1 complex thus requiring the 
bc1 complex to wait for a second molecule of quinol to come into the Qo site.   
The fact that there is a third substrate binding site allows for an enormous 
advancement in the study of the how the bc1 complex functions in the electron 
transfer chain.  It is interesting, however, to note the original Q-cycle hypothesis does 
an amazing job of mapping out the functioning of the bc1 complex under the 
assumption of only a two substrate binding site bc1 complex, which the notion of only 
two binding sites comes mainly from the study of available inhibitors for the bc1 
complex.  Of greater interest is the fact that the Q-cycle hypothesis was developed 
many years before the first bc1 complex structure was solved.   Further studies on the 
Qm binding site are currently in progress to describe in detail the reaction mechanism 
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